Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

  • Post published:March 24, 2022
  • Post category:Press Release
Read more about the article Nova Mentis Begins Enrollment in North American Autism Study

Nova Mentis Begins Enrollment in North American Autism Study

  • Post published:March 23, 2022
  • Post category:Press Release
Read more about the article Filament Health Announces Second Patent Issuance

Filament Health Announces Second Patent Issuance

  • Post published:March 23, 2022
  • Post category:Press Release
Read more about the article Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

  • Post published:March 23, 2022
  • Post category:Press Release
Read more about the article Awakn Life Sciences Announces Closing of Private Placement

Awakn Life Sciences Announces Closing of Private Placement

  • Post published:March 22, 2022
  • Post category:Press Release
Read more about the article Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

  • Post published:March 18, 2022
  • Post category:Psychedelic Bulletin
Read more about the article Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

  • Post published:March 17, 2022
  • Post category:Press Release
Read more about the article MINDCURE Provides Update on Strategic Review

MINDCURE Provides Update on Strategic Review

  • Post published:March 16, 2022
  • Post category:Press Release
Read more about the article Nova Mentis Announces Closing of Non-Brokered Financing

Nova Mentis Announces Closing of Non-Brokered Financing

  • Post published:March 15, 2022
  • Post category:Press Release
Read more about the article Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

  • Post published:March 15, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More